argenx NV ADR (ARGX)vsNuvalent Inc (NUVL)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
NUVL
Nuvalent Inc
$98.00
+1.92%
HEALTHCARE · Cap: $7.56B
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 30.5% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 63/100 (C+).
ARGX
Buy63
out of 100
Grade: C+
NUVL
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Intrinsic value data unavailable for NUVL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : NUVL
The strongest argument for NUVL centers on Altman Z-Score.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : NUVL
The primary concerns for NUVL are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
ARGX profiles as a growth stock while NUVL is a value play — different risk/reward profiles.
NUVL carries more volatility with a beta of 1.32 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (63/100 vs 25/100), backed by strong 30.5% margins and 73.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Nuvalent Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvalent Inc. is a pioneering clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients with genetically defined diseases. Leveraging its proprietary drug discovery platform, the company aims to create innovative treatments that specifically target genetic mutations responsible for tumor growth, thereby improving patient outcomes and minimizing side effects. With a robust pipeline of highly selective therapies, Nuvalent is strategically positioned within the precision oncology market, making it well-equipped to seize emerging opportunities in the rapidly evolving biotechnology sector. The company’s relentless commitment to advancing cancer treatment underscores its potential to significantly impact patient care in oncology.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?